The technology has been licensed by MGeneRx, which plans to commercialize it in the US first, then expand to low- and middle-income countries.
Although demand for the firm's COVID-19 testing declined in H1, other diagnostic areas and its international business have grown.
The Indian liquid biopsy company recently launched its Trublood tests for prostate cancer and pan-cancer detection using circulating tumor cells.
The liquid biopsy test compares fragments of cfDNA to a reference database of more than 1,400 microbial pathogens to determine infection.
The company previously launched its Concert Coding Engine to help standardize how genetic tests are coded and how labs can bill for them.
Originally developed to detect contamination of cell therapy products, the method combines CRISPR and PCR technology and can be used to quantify viral loads.
The proposed change would delete payable cancer codes if they contain the word "unspecified" even if the word is included in a code that doesn't impact coverage.
The instrument, which is undergoing the FDA clearance process, has the capability to do PCR testing, clinical chemistry, and immunoassays.
The company is working to transition its instruments sold in the US from COVID-19 testing to sepsis testing and increase its installed base.
The firm will submit its SARS-CoV-2 test and Talis One instrument to the US Food and Drug Administration for Emergency Use Authorization in the second quarter.